留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

急性高山病防治研究进展

熊娟 鹿辉 王荣 贾正平

熊娟, 鹿辉, 王荣, 贾正平. 急性高山病防治研究进展[J]. 药学实践与服务, 2017, 35(2): 97-101. doi: 10.3969/j.issn.1006-0111.2017.02.001
引用本文: 熊娟, 鹿辉, 王荣, 贾正平. 急性高山病防治研究进展[J]. 药学实践与服务, 2017, 35(2): 97-101. doi: 10.3969/j.issn.1006-0111.2017.02.001
XIONG Juan, LU Hui, WANG Rong, JIA Zhengping. Research progress on prevention and treatment of acute mountain sickness[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 97-101. doi: 10.3969/j.issn.1006-0111.2017.02.001
Citation: XIONG Juan, LU Hui, WANG Rong, JIA Zhengping. Research progress on prevention and treatment of acute mountain sickness[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 97-101. doi: 10.3969/j.issn.1006-0111.2017.02.001

急性高山病防治研究进展

doi: 10.3969/j.issn.1006-0111.2017.02.001
基金项目: 国家自然科学基金(81401552)

Research progress on prevention and treatment of acute mountain sickness

  • 摘要: 高海拔未习服人群快速进入高海拔地区易患急性高山病(acute mountain sickness,AMS)。AMS是一种以头痛为主要症状并伴有肠胃不适、眩晕、疲劳和失眠等症状的自限性疾病。虽然对AMS已经开展了大量研究,但业内对其病理机制以及有效防治等方面的认识还非常有限。深入认识AMS的诊断方法、危险因素和病理生理机制,对提出针对AMS有效的防治措施十分重要。本文基于课题组的前期研究和相关文献,较为系统地综述AMS的临床诊断、危险因素、病理生理机制和防治措施。
  • [1] Bartsch P,Swenson ER. Clinical practice:Acute high-altitude illnesses[J]. N Engl J Med,2013,368(24):2294-2302.
    [2] Gonggalanzi,Labasangzhu,Nafstad P,et al. Acute mountain sickness among tourists visiting the high-altitude city of Lhasa at 3658 m above sea level:a cross-sectional study[J]. Arch Public Health,2016,74(1):1-7.
    [3] Fruhauf A,Burtscher M,Pocecco E,et al. Subjective assessment of acute mountain sickness:investigating the relationship between the Lake Louise Self-Report,a visual analogue scale and psychological well-being scales[J]. Springerplus,2016,5(1):1646.
    [4] Wu J,Chen Y,Luo Y. Evaluation of the visual analog score (VAS) to assess acute mountain sickness (AMS) in a hypobaric chamber[J]. PLoS One,2014,9(11):e113376.
    [5] Fiore DC,Hall S,Shoja P. Altitude illness:risk factors,prevention,presentation,and treatment[J]. Am Fam Physician,2010,82(9):1103-1110.
    [6] Richalet JP,Larmignat P,Poitrine E,et al. Physiological risk factors for severe high-altitude illness:a prospective cohort study[J]. Am J Respir Crit Care Med,2012,185(2):192-198.
    [7] DiPasquale DM,Muza SR,Gunn AM,et al. Evidence for cerebral edema,cerebral perfusion,and intracranial pressure elevations in acute mountain sickness[J]. Brain Behav,2016,6(3):e00437.
    [8] Fischer R,Vollmar C,Thiere M,et al. No evidence of cerebral oedema in severe acute mountain sickness[J]. Cephalalgia,2004,24(1):66-71.
    [9] Bailey DM,Roukens R,Knauth M,et al. Free radical-mediated damage to barrier function is not associated with altered brain morphology in high-altitude headache[J]. J Cereb Blood Flow Metab,2006,26(1):99-111.
    [10] Dubowitz DJ,Dyer EA,Theilmann RJ,et al. Early brain swelling in acute hypoxia[J]. J Appl Physiol,2009,107(1):244-252.
    [11] Mairer K,Gobel M,Defrancesco M,et al. MRI evidence:acute mountain sickness is not associated with cerebral edema formation during simulated high altitude[J]. PLoS One,2012,7(11):e50334.
    [12] Wilson MH,Milledge J. Direct measurement of intracranial pressure at high altitude and correlation of ventricular size with acute mountain sickness:Brian Cummins' results from the 1985 Kishtwar expedition[J]. Neurosurgery,2008,63(5):970-974; discussion 974-975.
    [13] Hackett PH,Roach RC. High-altitude illness[J]. N Engl J Med,2001,345(2):107-114.
    [14] Van Osta A,Moraine JJ,Melot C,et al. Effects of high altitude exposure on cerebral hemodynamics in normal subjects[J]. Stroke,2005,36(3):557-560.
    [15] Julian CG,Subudhi AW,Hill RC,et al. Exploratory proteomic analysis of hypobaric hypoxia and acute mountain sickness in humans[J]. J Appl Physiol,2014,116(7):937-944.
    [16] Lopez JI,Holdridge A,Mendizabal JE. Altitude headache[J]. Curr Pain Headache Rep,2013,17(12):383.
    [17] Wilson MH,Davagnanam I,Holland G,et al. Cerebral venous system and anatomical predisposition to high-altitude headache[J]. Ann Neurol,2013,73(3):381-389.
    [18] Wilson MH,Imray CH,Hargens AR. The headache of high altitude and microgravity——similarities with clinical syndromes of cerebral venous hypertension[J]. High Alt Med Biol,2011,12(4):379-386.
    [19] Lu H,Wang R,Xiong J,et al. In search for better pharmacological prophylaxis for acute mountain sickness:looking in other directions[J]. Acta Physiol (Oxf),2015,214(1):51-62.
    [20] Schumacker PT. Lung cell hypoxia:role of mitochondrial reactive oxygen species signaling in triggering responses[J]. Proc Am Thorac Soc,2011,8(6):477-484.
    [21] Kayser B,Dumont L,Lysakowski C,et al. Reappraisal of acetazolamide for the prevention of acute mountain sickness:a systematic review and meta-analysis[J]. High Alt Med Biol,2012,13(2):82-92.
    [22] Luks AM,McIntosh SE,Grissom CK,et al. Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness:2014 update[J]. Wilderness Environ Med,2014,25(4 Suppl):S4-14.
    [23] Tang E,Chen Y,Luo Y. Dexamethasone for the prevention of acute mountain sickness:systematic review and meta-analysis[J]. Int J Cardiol,2014,173(2):133-138.
    [24] Pandit A,Karmacharya P,Pathak R,et al. Efficacy of NSAIDs for the prevention of acute mountain sickness:a systematic review and meta-analysis[J]. J Community Hosp Intern Med Perspect,2014,4(4).
    [25] Lipman GS,Kanaan NC. Ibuprofen for prevention of acute mountain sickness:is bigger really better[J]. Wilderness Environ Med,2013,24(2):177-178.
    [26] Sun L,Ding MJ,Cai TC,et al. Development and preliminary test of a new plateau hyperbaric chamber[J]. Am J Emerg Med,2015,33(10):1497-1500.
    [27] Shah NM,Hussain S,Cooke M,et al. Wilderness medicine at high altitude:recent developments in the field[J]. OAJSM,2015,6:319-328.
    [28] Grissom CK,Roach RC,Sarnquist FH,et al. Acetazolamide in the treatment of acute mountain sickness:Clinical efficacy and effect on gas exchange[J]. Ann Intern Med,1992,116(6):461-465.
    [29] Swenson ER. Pharmacology of acute mountain sickness:Old drugs and newer thinking[J]. J Appl Physiol,2016,120(2):204-215.
  • [1] 丁华敏, 郭羽晨, 秦春霞, 宋志兵, 孙莉莉.  消风止痒颗粒通过降低白三烯水平对小鼠特应性皮炎急性瘙痒的治疗作用研究 . 药学实践与服务, 2024, 42(5): 211-216. doi: 10.12206/j.issn.2097-2024.202306031
    [2] 徐飞, 陈瑾, 鲁育含, 李志勇.  肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023
  • 加载中
计量
  • 文章访问数:  3377
  • HTML全文浏览量:  325
  • PDF下载量:  371
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-08-30
  • 修回日期:  2016-11-07

急性高山病防治研究进展

doi: 10.3969/j.issn.1006-0111.2017.02.001
    基金项目:  国家自然科学基金(81401552)

摘要: 高海拔未习服人群快速进入高海拔地区易患急性高山病(acute mountain sickness,AMS)。AMS是一种以头痛为主要症状并伴有肠胃不适、眩晕、疲劳和失眠等症状的自限性疾病。虽然对AMS已经开展了大量研究,但业内对其病理机制以及有效防治等方面的认识还非常有限。深入认识AMS的诊断方法、危险因素和病理生理机制,对提出针对AMS有效的防治措施十分重要。本文基于课题组的前期研究和相关文献,较为系统地综述AMS的临床诊断、危险因素、病理生理机制和防治措施。

English Abstract

熊娟, 鹿辉, 王荣, 贾正平. 急性高山病防治研究进展[J]. 药学实践与服务, 2017, 35(2): 97-101. doi: 10.3969/j.issn.1006-0111.2017.02.001
引用本文: 熊娟, 鹿辉, 王荣, 贾正平. 急性高山病防治研究进展[J]. 药学实践与服务, 2017, 35(2): 97-101. doi: 10.3969/j.issn.1006-0111.2017.02.001
XIONG Juan, LU Hui, WANG Rong, JIA Zhengping. Research progress on prevention and treatment of acute mountain sickness[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 97-101. doi: 10.3969/j.issn.1006-0111.2017.02.001
Citation: XIONG Juan, LU Hui, WANG Rong, JIA Zhengping. Research progress on prevention and treatment of acute mountain sickness[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 97-101. doi: 10.3969/j.issn.1006-0111.2017.02.001
参考文献 (29)

目录

    /

    返回文章
    返回